J.P. Morgan Healthcare

Unifi launches Luxel, a new yarn blending linen's feel with performance tech and circular recycling, aiming to redefine sustainable fashion and home goods.

With its stock under pressure despite strong results, Box will use a key conference to prove its AI-powered content platform is the future of enterprise work.

A new J.D. Power study reveals that advanced technology, from infotainment to over-the-air software updates, is making modern vehicles less reliable.

With its lead drug in Phase 3, Celldex will update investors at three major conferences, highlighting its immunology pipeline and financial strategy.

As OneMain CEO Doug Shulman prepares for a key conference, all eyes are on the lender's strategy for navigating a complex economic and regulatory landscape.

As CFO Scott Ullem preps for a key presentation, Edwards balances record innovation and strong financials against new regulatory hurdles. What's at stake?

With booming exports and robust government backing, Italy is making a strategic play to become a global life sciences powerhouse. Here's what's driving the momentum.

With its new thalassemia drug AQVESME launching, Agios aims for blockbuster status while navigating a key safety warning and advancing a broad pipeline.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

With surging revenue for its cholesterol drugs and new guideline backing, Esperion outlines its strategy for profitability and pipeline expansion.

Fresh off a massive 240% revenue surge, Nutex Health prepares to showcase its micro-hospital model and physician-led strategy to top global investors.

PacBio heads to J.P. Morgan's conference with new tech aimed at making long-read sequencing cheaper. Can it challenge rivals and win over investors?

After a turbulent year, the sleep apnea device maker aims to prove its rocky product launch is behind it and convince investors of a strong 2026.